載入...
A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive, metastatic disease with limited treatment options. Factors contributing to the metastatic predisposition and therapy resistance in pancreatic cancer are not well understood. Here, we used a mouse model of KRAS-driven pancreatic carcinog...
Na minha lista:
| 發表在: | Oncotarget |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Impact Journals LLC
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4599239/ https://ncbi.nlm.nih.gov/pubmed/26158412 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|